Sellas Life Sciences Stock Net Income
| SLS Stock | USD 3.97 0.43 9.77% |
As of the 29th of January, Sellas Life has the Risk Adjusted Performance of 0.148, coefficient of variation of 528.82, and Semi Deviation of 5.14. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sellas Life Sciences, as well as the relationship between them. Please validate Sellas Life Sciences standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Sellas Life is priced more or less accurately, providing market reflects its prevalent price of 3.97 per share. Given that Sellas Life Sciences has jensen alpha of 1.36, we advise you to double-check Sellas Life Sciences's current market performance to make sure the company can sustain itself at a future point.
Sellas Life Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 20.8445 | Earnings Share (0.28) | Quarterly Revenue Growth (0.82) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.8 M | -29.2 M | |
| Net Loss | -35.5 M | -37.3 M | |
| Net Loss | -47.5 M | -49.9 M | |
| Net Loss | (0.05) | (0.05) | |
| Net Income Per E B T | 1.14 | 1.21 |
Sellas | Net Income | Build AI portfolio with Sellas Stock |
Latest Sellas Life's Net Income Growth Pattern
Below is the plot of the Net Income of Sellas Life Sciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Sellas Life Sciences financial statement analysis. It represents the amount of money remaining after all of Sellas Life Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Sellas Life's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sellas Life's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (30.88 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Sellas Net Income Regression Statistics
| Arithmetic Mean | (30,839,026) | |
| Coefficient Of Variation | (58.12) | |
| Mean Deviation | 12,447,508 | |
| Median | (27,792,900) | |
| Standard Deviation | 17,922,299 | |
| Sample Variance | 321.2T | |
| Range | 74.3M | |
| R-Value | 0.01 | |
| Mean Square Error | 342.5T | |
| R-Squared | 0.0002 | |
| Significance | 0.95 | |
| Slope | 53,229 | |
| Total Sum of Squares | 5139.3T |
Sellas Net Income History
Other Fundumenentals of Sellas Life Sciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Sellas Life Net Income component correlations
Sellas Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sellas Life is extremely important. It helps to project a fair market value of Sellas Stock properly, considering its historical fundamentals such as Net Income. Since Sellas Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sellas Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sellas Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Sellas introduce new products? Factors like these will boost the valuation of Sellas Life. If investors know Sellas will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Sellas Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sellas Life Sciences is measured differently than its book value, which is the value of Sellas that is recorded on the company's balance sheet. Investors also form their own opinion of Sellas Life's value that differs from its market value or its book value, called intrinsic value, which is Sellas Life's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Sellas Life's market value can be influenced by many factors that don't directly affect Sellas Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sellas Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sellas Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Sellas Life's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Sellas Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sellas Life's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sellas Life.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Sellas Life on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Sellas Life Sciences or generate 0.0% return on investment in Sellas Life over 90 days. Sellas Life is related to or competes with NeOnc Technologies, Mediwound, Genfit SA, Protara Therapeutics, Invivyd, Codexis, and OmniAb. SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer imm... More
Sellas Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sellas Life's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sellas Life Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.23 | |||
| Information Ratio | 0.1787 | |||
| Maximum Drawdown | 34.72 | |||
| Value At Risk | (8.17) | |||
| Potential Upside | 14.94 |
Sellas Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sellas Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sellas Life's standard deviation. In reality, there are many statistical measures that can use Sellas Life historical prices to predict the future Sellas Life's volatility.| Risk Adjusted Performance | 0.148 | |||
| Jensen Alpha | 1.36 | |||
| Total Risk Alpha | 0.7187 | |||
| Sortino Ratio | 0.2072 | |||
| Treynor Ratio | (105.14) |
Sellas Life January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.148 | |||
| Market Risk Adjusted Performance | (105.13) | |||
| Mean Deviation | 5.49 | |||
| Semi Deviation | 5.14 | |||
| Downside Deviation | 6.23 | |||
| Coefficient Of Variation | 528.82 | |||
| Standard Deviation | 7.22 | |||
| Variance | 52.2 | |||
| Information Ratio | 0.1787 | |||
| Jensen Alpha | 1.36 | |||
| Total Risk Alpha | 0.7187 | |||
| Sortino Ratio | 0.2072 | |||
| Treynor Ratio | (105.14) | |||
| Maximum Drawdown | 34.72 | |||
| Value At Risk | (8.17) | |||
| Potential Upside | 14.94 | |||
| Downside Variance | 38.86 | |||
| Semi Variance | 26.43 | |||
| Expected Short fall | (6.29) | |||
| Skewness | 0.321 | |||
| Kurtosis | 0.2224 |
Sellas Life Sciences Backtested Returns
Sellas Life is dangerous given 3 months investment horizon. Sellas Life Sciences owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.21, which indicates the firm had a 0.21 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.57% are justified by taking the suggested risk. Use Sellas Life Sciences Risk Adjusted Performance of 0.148, coefficient of variation of 528.82, and Semi Deviation of 5.14 to evaluate company specific risk that cannot be diversified away. Sellas Life holds a performance score of 16 on a scale of zero to a hundred. The entity has a beta of -0.0129, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sellas Life are expected to decrease at a much lower rate. During the bear market, Sellas Life is likely to outperform the market. Use Sellas Life Sciences value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Sellas Life Sciences.
Auto-correlation | 0.10 |
Insignificant predictability
Sellas Life Sciences has insignificant predictability. Overlapping area represents the amount of predictability between Sellas Life time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sellas Life Sciences price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Sellas Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.69 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sellas Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sellas Life Sciences reported net income of (30.88 Million). This is 109.05% lower than that of the Biotechnology sector and 144.09% lower than that of the Health Care industry. The net income for all United States stocks is 105.41% higher than that of the company.
Sellas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sellas Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sellas Life could also be used in its relative valuation, which is a method of valuing Sellas Life by comparing valuation metrics of similar companies.Sellas Life is currently under evaluation in net income category among its peers.
Sellas Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sellas Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sellas Life's managers, analysts, and investors.Environmental | Governance | Social |
Sellas Life Institutional Holders
Institutional Holdings refers to the ownership stake in Sellas Life that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sellas Life's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sellas Life's value.| Shares | Gsa Capital Partners Llp | 2025-06-30 | 426.6 K | Ubs Group Ag | 2025-06-30 | 309.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 294.1 K | Anson Funds Management Lp | 2025-06-30 | 275 K | Opus Capital Group Llc | 2025-06-30 | 240 K | Bank Of New York Mellon Corp | 2025-06-30 | 201.5 K | Two Sigma Investments Llc | 2025-06-30 | 197.6 K | Barclays Plc | 2025-06-30 | 172.8 K | Rhumbline Advisers | 2025-06-30 | 135.8 K | Vanguard Group Inc | 2025-06-30 | 6.7 M | Blackrock Inc | 2025-06-30 | 4.6 M |
Sellas Fundamentals
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 705.52 M | ||||
| Shares Outstanding | 170.28 M | ||||
| Shares Owned By Insiders | 0.77 % | ||||
| Shares Owned By Institutions | 23.73 % | ||||
| Number Of Shares Shorted | 42.04 M | ||||
| Price To Book | 16.42 X | ||||
| Price To Sales | 26.90 X | ||||
| Gross Profit | 900 K | ||||
| EBITDA | 632 K | ||||
| Net Income | (30.88 M) | ||||
| Cash And Equivalents | 26.99 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 1 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.36 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (35.4 M) | ||||
| Short Ratio | 3.12 X | ||||
| Earnings Per Share | (0.28) X | ||||
| Target Price | 6.83 | ||||
| Number Of Employees | 15 | ||||
| Beta | 2.27 | ||||
| Market Capitalization | 675.17 M | ||||
| Total Asset | 19.43 M | ||||
| Retained Earnings | (248.12 M) | ||||
| Working Capital | 6.82 M | ||||
| Net Asset | 19.43 M |
About Sellas Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sellas Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sellas Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sellas Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.